B3GAT1 and infection: As a first test of the potential of B3GAT1 expression as an antiviral strategy in vivo, we infected mice with Mal/04 (a mouse-adapted IBV) and found that exogenous B3GAT1 expression in the respiratory tract greatly improved infection outcome (Fig. 4l).